WO2010119294A2 - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- WO2010119294A2 WO2010119294A2 PCT/GB2010/050632 GB2010050632W WO2010119294A2 WO 2010119294 A2 WO2010119294 A2 WO 2010119294A2 GB 2010050632 W GB2010050632 W GB 2010050632W WO 2010119294 A2 WO2010119294 A2 WO 2010119294A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- material derived
- composition
- plant
- derived
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 239000000463 material Substances 0.000 claims abstract description 59
- 241001465754 Metazoa Species 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 241000001522 Terminalia chebula Species 0.000 claims abstract description 14
- 240000004482 Withania somnifera Species 0.000 claims abstract description 14
- 235000001978 Withania somnifera Nutrition 0.000 claims abstract description 14
- 235000010363 Vitex negundo Nutrition 0.000 claims abstract description 13
- 244000248021 Vitex negundo Species 0.000 claims abstract description 13
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 claims abstract description 13
- 240000004429 Tephrosia purpurea Species 0.000 claims abstract description 12
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 11
- 244000286838 Eclipta prostrata Species 0.000 claims abstract description 11
- 235000017517 Tephrosia purpurea Nutrition 0.000 claims abstract description 11
- 240000003428 Tinospora crispa Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
- 241000196324 Embryophyta Species 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 13
- 235000011517 Terminalia chebula Nutrition 0.000 claims description 8
- 208000019206 urinary tract infection Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000003908 liver function Effects 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000006052 feed supplement Substances 0.000 claims description 4
- 240000005748 Achyranthes aspera Species 0.000 claims description 3
- 235000005517 Achyranthes aspera Nutrition 0.000 claims description 3
- 235000018062 Boswellia Nutrition 0.000 claims description 3
- 240000007551 Boswellia serrata Species 0.000 claims description 3
- 241001130943 Phyllanthus <Aves> Species 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 3
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 3
- 244000071109 Terminalia arjuna Species 0.000 claims description 3
- 235000000538 Terminalia arjuna Nutrition 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004150 EU approved colour Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 230000002443 hepatoprotective effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 241000282326 Felis catus Species 0.000 description 13
- 206010035664 Pneumonia Diseases 0.000 description 10
- 244000309466 calf Species 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 241000283086 Equidae Species 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002012 ayurvedic medicine Substances 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000003 hoof Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 241000207965 Acanthaceae Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000009405 Ashwagandha Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 235000019780 Liver Tonic Nutrition 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241000250567 Tephrosia hamiltonii Species 0.000 description 1
- 241001312519 Trigonella Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000876 liver tonic Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention relates to a composition for oral administration comprising as active ingredient a combination of materials derived from plants, a process for preparing such a composition and its use in improving the general health of animals.
- the invention relates to an orally administrable composition comprising as active ingredient a combination of materials derived from plants which improves hepatic function in animals and is also useful in treating or preventing arthritis, urinary tract infections and respiratory infections .
- compositions based on plants or plant materials have been used for treating a variety of conditions in humans and animals.
- Combinations of herbs have traditionally been used in Ayurvedic medicine, for example.
- anti-arthritic preparations such as ElastinTM feed supplement suitable for use with dogs, cats and horses which comprises a combination of Boswellia Serrate gum, Glycyrrhiza Glabro roots, Curcuma longa, Tinospora Cordifolia stems, Trigonella foerum-graecum seeds, Vitex negundo , Withania Somnifera, Zingibar Officinale and Phyllanthus embelica fruits and Hepasan TM feed supplement , a liver tonic for dogs comprising a combination of Boehaaria diffusa, Terminalia arjuna, Eclipta alba, Terminalia chebula , Achyranthes aspera and Andrographis paniculata (all of which products are available from Ron Fields Nutrition, Hereford, UK) .
- feed supplements based on such specific combinations of herbal components for use in treating specific ailments in specific animals are commercially available, there remains a continuing need for the development of animal health products with improved effectiveness and range of applicability. In particular, there remains a need for the development of improved compositions for treating ailments in animals such as cats for which it is often considered that effective and commercially viable treatments are not available.
- the present invention is concerned with compositions which are effective in improving the general health of animals including humans.
- the compositions are effective in improving the health of domestic animals such as dogs and especially cats, as well as horses and cattle.
- the compositions are effective in improving liver function, as anti-arthritis agents in improving joint mobility and freedom of movement, and are also useful in protecting animals against infection.
- the invention provides a composition for oral administration comprising as active ingredient a combination of materials derived from the plants Andrographis paniculata , Tinospora Cordifolia, Eclipta alba, Tephrosia purpurea, Vitex negundo, Zinzibar officinale , Terminaliai chebula and Withania somnifera .
- the invention also provides a method for preparing such a composition and the use of such a composition in therapy of animals, and in protecting animals against infection. Further provided is a method of treating animals comprising administering to the animal an orally administrable composition as described above.
- an animal feed or animal chew composition comprising a composition according to the first aspect of the invention .
- a material derived from plants may comprise a whole plant or any constituent part thereof, such as a stem, leaf, seed, bark or root, which contains the biologically active component of the plant.
- composition according to the invention suitably comprises the leaves of the plant.
- Terminalia chebula the fruits of the plant are conveniently used.
- Zingiber officinale and Withania somnifera may suitably be used in the form of their roots .
- the plant material may be present as fragments of the plant, which may be obtained by chopping up the plant, or the material may be ground or otherwise processed by conventional techniques well known in the art to reduce the fragment size.
- the plant material may be formulated into an orally administrable preparation by suspending the fragments of plant material in water or some other suitable orally acceptable carrier conventional in the art.
- an extract of the plant materials may be prepared, for example by dissolving the plant material in a suitable solvent and filtering to remove unextracted plant matter
- the active ingredient may be prepared by mixing the constituent plant materials in the dry state and the pre-mixed active ingredient added to, or otherwise incorporated into, an animal feed composition.
- the pre-mixed active ingredient may be formed into pellets which may be added as a supplement to the normal diet or the active ingredient may be provided in powder form for use with an animal meal or treat.
- the active ingredient may be incorporated into an animal chew such that the active ingredient is delivered to the animal during chewing.
- the active ingredient may be formulated as a liquid which may be added to, sprayed onto or otherwise incorporated into, an animal feed composition.
- the liquid formulation may be sprayed directly into the mouth of the animal to which it is to be administered.
- the active ingredient of the compositions of the invention consists only of material from the plants Andrographis paniculata , Tinospora Cordi folia, Eclipta alba, Tephrosia purpurea , Vitex negundo, Zinzibar officinale , Terminalia chebula and Withania somnifera .
- composition according to the invention may comprise additional active ingredients such as material derived from one or more of the plants Phyllanthus embelica, Terminalia arjuna, Boswellia Serrate, Boehaaria diffusa and Achyranthes aspera.
- Andrographis paniculata commonly known in Ayurvedic medicine as Kalmegh, is a herbaceous plant of the Acanthaceae family, which is well known for treating infections and as an immunostimulant agent amongst other pharmacological activities.
- the Andrographis paniculata is suitably present in an amount of from 10 to 20 % of the total weight of plant-derived material in the composition, for example 15% of the total weight of plant- derived material in the composition.
- Tinospora Cordifolia a herbaceous vine of the family Menispermaceae which is indigenous to tropical India, is known as a hepatoprotectant and has been suggested for use in the treatment of arthiritis, jaundice and diabetes.
- Tinospora Cordifolia is suitably present in an amount of from 10 to 20 % of the total weight of plant-derived material in the composition, for example 15% of the total weight of plant- derived material in the composition.
- Eclipta alba is reputed to improve hair growth and colour and is indicated for use in viral hepatitis and memory disorders amongst many other indications .
- the Eclipta alba is suitably present in an amount of from 5 to 15 % of the total weight of plant- derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
- Tephrosia purpurea commonly known as Wild Indigo is used in Ayurvedic medicine for the treatment of a variety of disorders including rheumatism, asthma and urinary disorders.
- the Tephrosia purpurea is suitably present in an amount of from 5 to 15 % of the total weight of plant-derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
- Vitex negundo is reputed to have activity against rheumatic disorders and is indicated in the treatment of sciatica and to relieve catarrh and headache.
- the Vitex negundo is suitably present in an amount of from 10 to 30 % of the total weight of plant-derived material in the composition, for example 20% of the total weight of plant-derived material in the composition.
- Zinzibar officinale also known as ginger, is widely used in digestive, antitussive, antiflatulent, laxative and antacid compositions.
- the Zinzibar officinale is suitably present in an amount of from 5 to 15 % of the total weight of plant-derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
- Terminalia chebula is a deciduous tree native to southern Asia which is reputed in Ayurvedic medicine to cure blindness and to inhibit the growth of malignant tumours.
- the Terminalia chebula is suitably present in an amount of from 5 to 10 % of the total weight of plant-derived material in the composition, for example 7.5% of the total weight of plant-derived material in the composition.
- Withania somnifera commonly known as Ashwagandha, is traditionally used as an aphrodisiac, a diuretic and for treating memory loss.
- the Withania somnifera is suitably present in an amount of from 5 to 10 % of the total weight of plant-derived material in the composition, for example 7.5% of the total weight of plant-derived material in the composition.
- the compositions according to the invention may also suitably comprise one or more additional orally acceptable excipients conventional in the art such as sweeteners, colouring agents and preservatives.
- compositions comprising as active ingredient a combination of materials derived from the above mentioned plants are particularly effective in improving liver function in animals, in particular domestic animals such as dogs and especially cats, without adverse effects.
- the compositions according to the invention improve joint mobility and freedom of movement and are useful in the treatment of urinary tract infections, thereby contributing to the overall improvement in general health of the animal concerned.
- the compositions of the invention are not limited in their applicability to cats and dogs, however, and are also effective in treating other animals, such as cattle and horses.
- compositions of the invention have been found to be effective in promoting recovery where animals show general symptoms of disease, even where the underlying cause has not been diagnosed.
- the compositions of the invention are effective in treating cats suffering from a wide range of symptoms including loss of fur, itching, abdominal spots, lethargy, loss of appetite, diarrhea, digestive problems, abscesses and sores. These symptoms are often associated with feline AIDS and the compositions of the invention are therefore useful in ameliorating symptoms in cats suffering from this disease .
- compositions of the invention are also effective in treating a range of conditions in dogs, such as blister and hair loss, and also hoof problems in horses including blisters, cracking and fungal infections.
- the compositions of the invention have been found to be particularly effective in preventing the development of pneumonia and in treating mastitis.
- a composition according to the invention has the composition as shown in table 1 Table 1
- Andrographis paniculata plant 15 Tinospora Cordifolia stems 15 Eclipta alba plant 10 Tephrosia purpurea leaves 10 Vitex negundo leaves 20 Zinzibar officinale roots 15 Terminaliai chebula fruits 7.5 Withania somnifera roots 7.5
- composition of table 1 when formulated as a liquid and sprayed onto cat food has been found to improve liver function and also to treat urinary tract infections and improve joint mobility. Cats suffering from impaired liver function and which would otherwise normally not be expected to survive have been found to make full recoveries.
- a herd of two hundred cows brought into housing for the winter months was treated with the above composition. Prior to being treated with the composition, the cows had very high cell counts, averaging 2,000,000 for each of the three months prior to treatment. After treatment with the composition (at a rate of 4 kg per ton of feed) for a month, the cell count was found to have dropped to a normal level of 800,000 and this level was maintained with continued administration of the composition over the following three months. When administration of the composition was stopped, the next monthly cell count retuned to the previous high count of 2,000,000.
- horses suffering from various hoof problems such as fungus, blisters and cracking hooves which had proved resistant to treatment with conventional veterinary antibiotics were treated with the above composition formulated as a liquid. All of the treated horses recovered within a month.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
The invention provides a composition for oral administration comprising as active ingredient a combination of material derived from the plants Andrographis paniculata, Tinospora Cordifolia, Eclipta alba, Tephrosia purpurea, Vitex negundo, Zinzibar officinale, Terminaliai chebula and Withania somnifera. Methods for preparing such a composition and the use of such a composition in therapy of animals are also provided.
Description
COMPOSITION
Field of the Invention
The present invention relates to a composition for oral administration comprising as active ingredient a combination of materials derived from plants, a process for preparing such a composition and its use in improving the general health of animals. In particular, the invention relates to an orally administrable composition comprising as active ingredient a combination of materials derived from plants which improves hepatic function in animals and is also useful in treating or preventing arthritis, urinary tract infections and respiratory infections .
Background of the Invention
Compositions based on plants or plant materials have been used for treating a variety of conditions in humans and animals. Combinations of herbs have traditionally been used in Ayurvedic medicine, for example.
Various combinations of plants or plant materials have been advocated for use in a variety of conditions, such as treating disorders of the immune system, cardiovascular diseases and as hepatoprotective agents.
Commercially available products comprising combinations of herbal components of use in improving the general health of animals include anti-arthritic preparations such as Elastin™ feed supplement suitable for use with dogs, cats and horses which comprises a combination of Boswellia Serrate gum, Glycyrrhiza Glabro roots, Curcuma longa, Tinospora Cordifolia stems, Trigonella foerum-graecum seeds, Vitex negundo , Withania Somnifera, Zingibar Officinale and Phyllanthus embelica fruits and Hepasan ™ feed supplement , a liver tonic for dogs
comprising a combination of Boehaaria diffusa, Terminalia arjuna, Eclipta alba, Terminalia chebula , Achyranthes aspera and Andrographis paniculata (all of which products are available from Ron Fields Nutrition, Hereford, UK) .
Although feed supplements based on such specific combinations of herbal components for use in treating specific ailments in specific animals are commercially available, there remains a continuing need for the development of animal health products with improved effectiveness and range of applicability. In particular, there remains a need for the development of improved compositions for treating ailments in animals such as cats for which it is often considered that effective and commercially viable treatments are not available.
Summary of the Invention
The present invention is concerned with compositions which are effective in improving the general health of animals including humans. In particular the compositions are effective in improving the health of domestic animals such as dogs and especially cats, as well as horses and cattle. The compositions are effective in improving liver function, as anti-arthritis agents in improving joint mobility and freedom of movement, and are also useful in protecting animals against infection.
In a first aspect, the invention provides a composition for oral administration comprising as active ingredient a combination of materials derived from the plants Andrographis paniculata , Tinospora Cordifolia, Eclipta alba, Tephrosia purpurea, Vitex negundo, Zinzibar officinale , Terminaliai chebula and Withania somnifera .
The invention also provides a method for preparing such a composition and the use of such a composition in therapy of animals, and in protecting animals against infection.
Further provided is a method of treating animals comprising administering to the animal an orally administrable composition as described above.
Also provided is an animal feed or animal chew composition comprising a composition according to the first aspect of the invention .
Detailed description of the invention
As used herein, a material derived from plants may comprise a whole plant or any constituent part thereof, such as a stem, leaf, seed, bark or root, which contains the biologically active component of the plant.
Suitable such constituent parts containing the biologically active component of the plant will depend on the particular plant concerned, as will be understood by the average skilled person in the art. Where the plant is Tephrosia purpurea or Vitex negundo, for example, then in one embodiment the composition according to the invention suitably comprises the leaves of the plant. In the case of Terminalia chebula, the fruits of the plant are conveniently used. Zingiber officinale and Withania somnifera may suitably be used in the form of their roots .
The plant material may be present as fragments of the plant, which may be obtained by chopping up the plant, or the material may be ground or otherwise processed by conventional techniques well known in the art to reduce the fragment size.
Conveniently, the plant material may be formulated into an orally administrable preparation by suspending the fragments of plant material in water or some other suitable orally acceptable carrier conventional in the art.
In another embodiment, an extract of the plant materials may be prepared, for example by dissolving the plant material in a suitable solvent and filtering to remove unextracted plant matter
In one embodiment, the active ingredient may be prepared by mixing the constituent plant materials in the dry state and the pre-mixed active ingredient added to, or otherwise incorporated into, an animal feed composition.
Suitably, the pre-mixed active ingredient may be formed into pellets which may be added as a supplement to the normal diet or the active ingredient may be provided in powder form for use with an animal meal or treat.
In an alternative embodiment, the active ingredient may be incorporated into an animal chew such that the active ingredient is delivered to the animal during chewing.
In another embodiment, the active ingredient may be formulated as a liquid which may be added to, sprayed onto or otherwise incorporated into, an animal feed composition. Alternatively, the liquid formulation may be sprayed directly into the mouth of the animal to which it is to be administered.
In one embodiment, the active ingredient of the compositions of the invention consists only of material from the plants Andrographis paniculata , Tinospora Cordi folia, Eclipta alba, Tephrosia purpurea , Vitex negundo, Zinzibar officinale , Terminalia chebula and Withania somnifera .
In another embodiment, the composition according to the invention may comprise additional active ingredients such as material derived from one or more of the plants Phyllanthus
embelica, Terminalia arjuna, Boswellia Serrate, Boehaaria diffusa and Achyranthes aspera.
Andrographis paniculata , commonly known in Ayurvedic medicine as Kalmegh, is a herbaceous plant of the Acanthaceae family, which is well known for treating infections and as an immunostimulant agent amongst other pharmacological activities. In the active ingredient according to the present invention, the Andrographis paniculata is suitably present in an amount of from 10 to 20 % of the total weight of plant-derived material in the composition, for example 15% of the total weight of plant- derived material in the composition.
Tinospora Cordifolia, a herbaceous vine of the family Menispermaceae which is indigenous to tropical India, is known as a hepatoprotectant and has been suggested for use in the treatment of arthiritis, jaundice and diabetes. In the active ingredient according to the present invention, Tinospora Cordifolia is suitably present in an amount of from 10 to 20 % of the total weight of plant-derived material in the composition, for example 15% of the total weight of plant- derived material in the composition.
Eclipta alba is reputed to improve hair growth and colour and is indicated for use in viral hepatitis and memory disorders amongst many other indications . In the active ingredient according to the invention, the Eclipta alba is suitably present in an amount of from 5 to 15 % of the total weight of plant- derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
Tephrosia purpurea, commonly known as Wild Indigo is used in Ayurvedic medicine for the treatment of a variety of disorders including rheumatism, asthma and urinary disorders. In the active ingredient according to the invention, the Tephrosia purpurea is suitably present in an amount of from 5 to 15 % of
the total weight of plant-derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
Vitex negundo is reputed to have activity against rheumatic disorders and is indicated in the treatment of sciatica and to relieve catarrh and headache. In the active ingredient according to the invention, the Vitex negundo is suitably present in an amount of from 10 to 30 % of the total weight of plant-derived material in the composition, for example 20% of the total weight of plant-derived material in the composition.
Zinzibar officinale , also known as ginger, is widely used in digestive, antitussive, antiflatulent, laxative and antacid compositions. In the active ingredient according to the invention, the Zinzibar officinale is suitably present in an amount of from 5 to 15 % of the total weight of plant-derived material in the composition, for example 10% of the total weight of plant-derived material in the composition.
Terminalia chebula , known as Black Myrobalan, is a deciduous tree native to southern Asia which is reputed in Ayurvedic medicine to cure blindness and to inhibit the growth of malignant tumours. In the active ingredient according to the invention, the Terminalia chebula is suitably present in an amount of from 5 to 10 % of the total weight of plant-derived material in the composition, for example 7.5% of the total weight of plant-derived material in the composition.
Withania somnifera , commonly known as Ashwagandha, is traditionally used as an aphrodisiac, a diuretic and for treating memory loss. In the active ingredient according to the invention, the Withania somnifera is suitably present in an amount of from 5 to 10 % of the total weight of plant-derived material in the composition, for example 7.5% of the total weight of plant-derived material in the composition.
The compositions according to the invention may also suitably comprise one or more additional orally acceptable excipients conventional in the art such as sweeteners, colouring agents and preservatives.
The present inventor has found that compositions comprising as active ingredient a combination of materials derived from the above mentioned plants are particularly effective in improving liver function in animals, in particular domestic animals such as dogs and especially cats, without adverse effects. In addition, the compositions according to the invention improve joint mobility and freedom of movement and are useful in the treatment of urinary tract infections, thereby contributing to the overall improvement in general health of the animal concerned. The compositions of the invention are not limited in their applicability to cats and dogs, however, and are also effective in treating other animals, such as cattle and horses.
The compositions of the invention have been found to be effective in promoting recovery where animals show general symptoms of disease, even where the underlying cause has not been diagnosed. Thus, for example, the compositions of the invention are effective in treating cats suffering from a wide range of symptoms including loss of fur, itching, abdominal spots, lethargy, loss of appetite, diarrhea, digestive problems, abscesses and sores. These symptoms are often associated with feline AIDS and the compositions of the invention are therefore useful in ameliorating symptoms in cats suffering from this disease .
The compositions of the invention are also effective in treating a range of conditions in dogs, such as blister and hair loss, and also hoof problems in horses including blisters, cracking and fungal infections.
In cattle, the compositions of the invention have been found to be particularly effective in preventing the development of pneumonia and in treating mastitis.
Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", mean "including but not limited to", and do not exclude other moieties, additives, components, integers or steps.
As used herein, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Preferred features of each aspect of the invention may be as described in connection with any of the other aspects.
Other features of the present invention will become apparent from the following example. Generally speaking the invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims and drawings) . Thus features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
Examples
A composition according to the invention has the composition as shown in table 1
Table 1
Material Amount ow/w)
Andrographis paniculata plant 15 Tinospora Cordifolia stems 15 Eclipta alba plant 10 Tephrosia purpurea leaves 10 Vitex negundo leaves 20 Zinzibar officinale roots 15 Terminaliai chebula fruits 7.5 Withania somnifera roots 7.5
Example 1 Treatment of various symptoms in cats
The composition of table 1 when formulated as a liquid and sprayed onto cat food has been found to improve liver function and also to treat urinary tract infections and improve joint mobility. Cats suffering from impaired liver function and which would otherwise normally not be expected to survive have been found to make full recoveries.
Ten cats suffering from a range of symptoms, including loss of fur and itching, urinary tract infections, lethargy, diarrohea, digestive problems and general illness, abcesses and oozing sores, some of which are associated with feline AIDS, were fed twice a day with feed sprayed with the above composition. Eight of these cats had previously been treated with antibiotics but had failed to recover.
After being treated with the composition of the invention, all ten cats recovered within a few days, some within 24 hours. Their general appearance was observed to have improved and lethargy and nervousness disappeared. Appetite also returned generally and abcesses cleared up within a week to ten days.
Example 2
Protection against pneumonia in cattle
In a trial lasting a month, six calves were fed with the above composition added in an amount of 5ml/day to their milk. The incidence of pneumonia occurring in the group was monitored and compared to the incidence of pneumonia in a control group of six calves not fed with the composition.
Of the six calves treated with the composition according to the invention, only one developed pneumonia whereas in the control group, three out of the six calves developed pneumonia. Following administration of 5cc of chloramphenicol, all of the calves on the trial that developed pneumonia recovered.
In a further trial, eight calves were fed the composition in an amount of 5 ml/day added to their milk every day for a month and another group of calves were fed the composition in an amount of 10 ml/day every day for a month. Only one of the calves in the group having 5 ml composition/day added to their milk developed pneumonia and none of the calves being administered with 10 ml/day of the composition developed pneumonia. By contrast, four out of the eight calves in the control group which were not fed with the composition developed pneumonia.
Example 3
Reduction of high cell count in cattle
A herd of two hundred cows brought into housing for the winter months was treated with the above composition. Prior to being treated with the composition, the cows had very high cell counts, averaging 2,000,000 for each of the three months prior to treatment. After treatment with the composition (at a rate of 4 kg per ton of feed) for a month, the cell count was found to
have dropped to a normal level of 800,000 and this level was maintained with continued administration of the composition over the following three months. When administration of the composition was stopped, the next monthly cell count retuned to the previous high count of 2,000,000.
In another test group on a different farm, five cows with individual high cell counts were fed with 25 ml/day of the above composition. After one month, each cow's cell count was found to have been reduced by 70%, rendering it normal.
Experiment 4
Treatment of various symptoms in dogs
Five dogs suffering from blisters and/or losing hair were treated with the above composition formulated as a liquid. Within one month, the coats of all of the dogs were found to have recovered.
Experiment 5
Treatment of various symptoms in horses
In four separate trials, horses suffering from various hoof problems such as fungus, blisters and cracking hooves which had proved resistant to treatment with conventional veterinary antibiotics were treated with the above composition formulated as a liquid. All of the treated horses recovered within a month.
Claims
1. A composition for oral administration comprising as active ingredient a combination of materials derived from the plants Andrographis paniculata , Tinospora Cordi folia , Eclipta alba, Tephrosia purpurea , Vitex negundo, Zinzibar officinale , Terminaliai chebula and Withania somnifera .
2. A composition according to claim 1 further comprising an additional active ingredient comprising material derived from one or more of the plants Phyllanthus embelica, Terminalia arjuna, Boswellia Serrate, Boehaaria diffusa and Achyranthes aspera .
3. A composition according to claim 1 wherein the active ingredient consists of a combination of material derived from the plants Andrographis paniculata , Tinospora Cordifolia , Eclipta alba, Tephrosia purpurea , Vitex negundo, Zinzibar officinale , Terminaliai chebula and Withania somnifera .
4. A composition according to any of claims 1 to 3 wherein the material derived from the plants Tephrosia purpurea or Vitex negundo comprises the leaves of the plant.
5. A composition according to any preceding claim wherein the material derived from the plant Terminalia chebula is the fruit of the plant.
6. A composition according to any preceding claim wherein the material derived from the plants Zingiber officinale and
Withania somnifera is the root of the plant.
7. A composition according to any preceding claim wherein the active ingredient comprises, by % weight of the total weight of plant-derived material in the composition, from 10 to 20% of material derived from Andrographis paniculata , from 10 to 20% of material derived from Tinospora Cordifolia f from 5 to 15% of material derived from Eclipta alba , from 5 to 15% of material derived from Tephrosia purpurea , from 10 to 30% of material derived from Vitex negundo, from 5 to 15% of material derived from Zinzibar officinale , from 5 to 10% of material derived from Terminalia chebula and from 5 to 10% of material derived from Withania somnifera .
8. A composition according to claim 7 wherein the active ingredient comprises, by % weight of the total weight of plant- derived material in the composition, 15% of material derived from Andrographis paniculata , 15% of material derived from Tinospora Cordifolia ,10% of material derived from Eclipta alba, 10% of material derived from Tephrosia purpurea , 20% of material derived from Vitex negundo, 10% of material derived from Zinzibar officinale , 7.5% of material derived from Terminalia chebula and 7.5% of material derived from Withania somnifera .
9. A composition according to any preceding claim further comprising one or more orally acceptable excipients selected from sweeteners, colouring agents and preservatives.
10. A composition according to any of claims 1 to 9 in the form of a dry mixture
11. A composition according to any of claims 1 to 9 in the form of a liquid or spray.
12. A composition according to any of claims 1 to 9 in the form of a pellet.
13. An animal feed composition comprising a composition according to any preceding claim.
14. An animal chew comprising a composition according to any of claims 1 to 12.
15. A method for preparing a composition according to any of claims 1 to 9 comprising mixing the constituent plant materials and optional additional orally acceptable excipients.
16. Use of a composition according to any of claims 1 to 12 for use in therapy in animals.
17. Use of a composition according to any of claims 1 to 12 as a feed supplement for an animal feed composition.
18. Use of a composition according to any of claims 1 to 12 in the manufacture of a medicament for use as a hepatoprotective agent or in the treatment of arthiritis, urinary tract infections or respiratory infections in animals.
19. A feed composition according to claim 13 for use in improving liver function in animals or in the treatment of arthiritis, urinary tract infections or respiratory infections in animals .
20. A method of treating animals comprising administering to the animal an orally administrable composition according to any one of claims 1 to 12.
21. A method of treating animals comprising feeding the animal with a feed composition according to claim 13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0906548.3 | 2009-04-16 | ||
GBGB0906548.3A GB0906548D0 (en) | 2009-04-16 | 2009-04-16 | Composition |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010119294A2 true WO2010119294A2 (en) | 2010-10-21 |
WO2010119294A3 WO2010119294A3 (en) | 2010-12-09 |
Family
ID=40750696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/050632 WO2010119294A2 (en) | 2009-04-16 | 2010-04-16 | Composition |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB0906548D0 (en) |
WO (1) | WO2010119294A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104771741A (en) * | 2015-04-27 | 2015-07-15 | 朱增伟 | Traditional Chinese medicine composition for treating chronic enteritis |
WO2015068112A3 (en) * | 2013-11-06 | 2015-08-13 | Anil Kumar Sharma | Herbal composition for treatment of hypertension and associated disorders |
US10953067B2 (en) | 2014-02-05 | 2021-03-23 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2524664C1 (en) * | 2013-04-23 | 2014-07-27 | ГОСУДАРСТВЕННОЕ НАУЧНОЕ УЧРЕЖДЕНИЕ СИБИРСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ СЕЛЬСКОГО ХОЗЯЙСТВА И ТОРФА РОССИЙСКОЙ АКАДЕМИИ СЕЛЬСКОХОЗЯЙСТВЕННЫХ НАУК (ГНУ СибНИИСХиТ Россельхозакадемии) | Method of prevention of mass gastrointestinal and respiratory diseases of suckling pigs |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
US6517861B2 (en) * | 2001-01-22 | 2003-02-11 | Council Of Scientific And Industrial Research | Composition of herbal biscuits for lactating mothers acting as dietary supplement and process for preparation thereof |
WO2006061675A1 (en) * | 2004-12-10 | 2006-06-15 | Council Of Scientific & Industrial Research | Anti-arthritic herbal composition and method of production thereof |
WO2007093897A2 (en) * | 2006-02-16 | 2007-08-23 | Promed Exports Private Limited | Process of making herbal composition with masked bitter taste and product thereof |
-
2009
- 2009-04-16 GB GBGB0906548.3A patent/GB0906548D0/en not_active Ceased
-
2010
- 2010-04-16 WO PCT/GB2010/050632 patent/WO2010119294A2/en active Application Filing
- 2010-04-16 GB GB1006350A patent/GB2469577A/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
None |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015068112A3 (en) * | 2013-11-06 | 2015-08-13 | Anil Kumar Sharma | Herbal composition for treatment of hypertension and associated disorders |
US10953067B2 (en) | 2014-02-05 | 2021-03-23 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
US11903991B2 (en) | 2014-02-05 | 2024-02-20 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
CN104771741A (en) * | 2015-04-27 | 2015-07-15 | 朱增伟 | Traditional Chinese medicine composition for treating chronic enteritis |
Also Published As
Publication number | Publication date |
---|---|
GB201006350D0 (en) | 2010-06-02 |
GB0906548D0 (en) | 2009-05-20 |
WO2010119294A3 (en) | 2010-12-09 |
GB2469577A (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2236149B1 (en) | Medicinal composition for treating respiratory infectious diseases | |
JP3007665B2 (en) | Preventive and therapeutic agent for coronavirus infection and disinfectant | |
CN103006916A (en) | Pure traditional Chinese medicine recipe for curing various animal diarrhoeal diseases and preparation method of pure traditional Chinese medicine recipe | |
WO2010119294A2 (en) | Composition | |
CN102670780A (en) | Antidysenteric for livestock and poultry and preparation method thereof | |
Kamatchi et al. | Quantitative analysis in traditional knowledge of wild medicinal plants used to treat livestock diseases by The Paliyar’s Tribe of Sadhuragiri Hillstamil Nadu, India | |
CN110507771B (en) | Medicine for preventing and treating animal digestive syndrome and preparation method thereof | |
CN108096355B (en) | Traditional Chinese medicine compound formula for treating cold-dampness type diarrhea of pigs, preparation and application | |
CN113181317B (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preventing diarrhea or resisting diarrhea | |
KR20090094617A (en) | Antibiotic, anti-inflammatory and immunologically enhancing composition | |
CN114470042A (en) | Composition for preventing and treating animal liver injury and preparation method and application thereof | |
CN103283958B (en) | Formulation and preparation method of Chinese herbal feed additive for livestock and poultry | |
KR20220006183A (en) | Feed additive using herbal medicine and method for manufacturing thereof | |
KR101800870B1 (en) | Composition for improving livestock immunity comprising probiotics as effective component | |
EP2680924B1 (en) | A novel herbal composition for the treatment of kidney stone and other urinary tract disorders | |
Dhana | Multiple Beneficial Applications and Modes of Action of Herbs in Poultry | |
RU2370274C1 (en) | Bioactive veterinary drug and method of non-specific resistanse improval for calves using drug | |
Kumar et al. | Pharmacological properties of tulsi: A review | |
RU2309762C1 (en) | Method for preventing respiratory diseases in calves | |
CN116898937B (en) | Chinese herbal medicine composition and powder for preventing and treating colibacillosis of poultry and application of Chinese herbal medicine composition and powder | |
CN115671192B (en) | Traditional Chinese medicine composition for preventing and treating taeniasis of ducks | |
WO2012131650A1 (en) | Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases | |
KR102691231B1 (en) | Treatment for calf diarrhea | |
RU2508119C1 (en) | HERBAL TREMATOCIDAL DRUG FOR EXCYSTED LARVAE Fasciola hepatica | |
Priya et al. | Treatment of enteritis in goats with traditional ethno-veterinary medicine formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10720188 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10720188 Country of ref document: EP Kind code of ref document: A2 |